Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
1.20%
)
US TECH 100
25,958.00
(
1.32%
)
Dow Jones
49,447.43
(
1.88%
)
Brent Oil
88.87
(
-6.47%
)
Bitcoin
77,392.51
(
2.94%
)
News Focus
News Focus
Post# of 257422
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122875
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 241772

Wednesday, 03/23/2022 5:22:46 PM

Wednesday, March 23, 2022 5:22:46 PM

Post# of 257422
NVS’ 2017 entry into radioligand field:

https://www.reuters.com/article/us-novartis-advanced-accelerator/novartis-to-buy-french-cancer-specialist-aaa-for-3-9-billion-idUSKBN1CZ0HC

NVS acquired AAAP in Oct 2017, thereby gaining ownership of Lutathera, a radioligand for neuroendocrine tumors. NVS paid a 47% premium in an all-cash deal valued at $3.9B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today